Gray, Nathanael,Zhang, Tinghu,Ciblat, Stephane,Leblanc, Melissa,Marineau, Jason J.,Moore, Joel,Sprott, Kevin,Siddiqui, M. Arshad,Kabro, Anzhelika,Miller, Tom,Roy, Stephanie,Schmidt, Darby,Winter, Dana
申请号：
AU2014337044
公开号：
AU2014337044A1
申请日:
2014.10.17
申请国别(地区):
AU
年份:
2016
代理人:
摘要：
The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing' s sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.
